Pergamum to Provide Effective Development of Innovative Dermatology and Wound Healing Companies
The Pergamum product pipeline consists of five development projects,three of which are undergoing clinical trials. Indications covered within theportfolio include improved wound healing and reduced scar formation, healinghard-to-heal-wounds, the prevention of bacterial and fungal infections,atopic dermatitis and infected wounds and burns.
Pergamum CEO Magnus Precht will present Pergamum at the Rodman & RenshawAnnual Global Investment Conference in New York September 9-11, 2009 and willbe available for one-on-one meetings with investors and potential partnersduring the conference.
"Pergamum represents a unique approach to developing newbiopharmaceuticals in the dermatology and wound care markets," said MagnusPrecht, CEO of Pergamum AB. "The fact that the group is working withinrelated fields means we are able to build capabilities and specialistknowledge tailored to the needs of the group. We will provide individualprojects with access to technical skills and key competencies withoutcreating bureaucratic layers. This should translate into improved quality,cost savings and, ultimately, a shorter path to regulatory approval. It alsomeans we have a broader, more attractive offering when meeting with pharmacompanies to discuss eventual sales or licensing opportunities," added MrPrecht.
Pergamum's current projects include: wound healing (Omnio Healer), atopicdermatitis / anti-inflamatory (BioCis Pharma), atopic dermatitis /anti-infective (DermaGen), anti-adhesion / wound healing (PharmaSurgics), andwound healing for chronic wounds (Lipopeptide). Karolinska Development owns64% of Pergamum, with the other owners being Ostersjostiftelsen (TheFoundation for Baltic and East European Studies) and Midroc New Technology.
Karolinska Development's CEO, Conny Bogentoft, said, "We are extremelypleased with this new initiative. By consolidating all of our interests inthe dermatology and wound healing field in this way we have created anextremely resource-efficient business model. It should provide both moreeffective project development and greater efficiency when seeking exitopportunities."
About Karolinska Development:
Managing one of the largest portfolios of life science research companiesin Europe, Karolinska Development
AB is a new type of company focused on filling the innovation gap withinthe pharmaceutical industry. Using a unique, highly cost-effective modelKarolinska Development commercializes internationally renowned life scienceinnovations, helping to deliver the medical products of the future.For more information please contact: Magnus Precht, CEO, Pergamum AB European mobile phone: +46-73-515-7450 US cell phone: +1-817-312-7277 email@example.com http://www.pergamum.com Conny Bogentoft, CEO, Karolinska Development AB Cell phone: +46-70-668-61-43 firstname.lastname@example.org http://www.karolinskadevelopment.com
SOURCE Karolinska Development AB
You May Also Like